Eli Lilly of Indiana received permission for restricted emergency use from India's Central Drugs Standard Control Organization, for baricitinib in combination with remdesivir, for treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The company has...